CAMBRIDGE, UK, 5 November 2021 - today bit.bio announces the first close of their Series B financing of $103 million.
New and existing institutional and strategic investors in the Series B round, thus far, include Arch Ventures, Charles River Laboratories, Foresite Capital, National Resilience, Inc. (Resilience), Metaplanet, Puhua Capital and Tencent.
News
Marks & Clerk, one of the world’s leading intellectual property (IP) law firms, has announced the promotion of Andrea Williams to Partner and the appointment of Senior Associate David Kemp to the Cambridge team, transferring from the London office. Both attorneys are part of the firm’s market-leading UK teams, with Andrea specialising in patents in the biotechnology field and David advising on all aspects of UK, EUTM and international trade mark law and practice. “I am delighted to announce the promotion of Andrea Williams to Partner, and welcome David Kemp to Cambridge.
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITH
A LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER PRODUCT
Cambridge, UK, 1 November 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with a leading global medical products company.
Closed Loop Medicine has closed £13 million GBP (c. $17million USD) of new investment from a range of top UK and European venture capital investors. The money has been raised to finance its personalised drug + digital therapy (DTx) combination products which are being developed to improve outcomes for patients and clinicians through precision dosing.
This is the second time writing about the Neurim v Mylan battle “take two” concerning a divisional patent (EP 3 103 443) granted on 30 June 2021 (but expires 12 August 2022). The first article (Neurim v Mylan: Take Two) covered Neurim’s successful application for an expedited preliminary issue trial. That article also covers (some of) the twists and turns of the original Neurim v Mylan battle on the parent patent.
CAMBRIDGE, United Kingdom, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionizing genome sequencing, today announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million. Temasek led the Series D round with participation from new investors including Third Point and existing investors such as GV, New Science Ventures, Ahren Innovation Capital and Sequoia.
Cambridge, UK, 02 November 2021: Mogrify Limited (Mogrify®), a biopharmaceutical company pioneering the development of a new class of in vivo reprogramming therapies and transforming the development of ex vivo cell therapies, today announced the appointment of Tom Graney CFA as Non-Executive Director, Audit Chair and Capital Markets Advisor. He joins senior biopharma industry executives, Dr. Jane Osbourn OBE (Chair) and Dr. Lorenz Mayr, as an independent member of the Board of Directors.
Commenting in reaction to the Chancellor’s budget on 27th October 2021, Dr Peter Jackson, executive director, Infex Therapeutics, said:
“The announcement today that the government is increasing public R&D investment to record levels to cement the UK as a global science and technology superpower is hugely encouraging news, and reflects the importance of innovative, entrepreneurial companies to the future economic wellbeing of our country as we seek to recover from the pandemic.
"Diagnostics - More important than ever, but there's still a way to go".
Diagnostics are clearly improving and enabling better clinical decisions to be made, especially in oncology where mutation detection is enabling much more personalised approaches to treatment. There is still a long way to go, but combinations of diagnostics tests and technologies (beyond genomics) are giving a more detailed picture on which to base treatment decisions.